Chemical and Engineering News looked at the question of “How will FDA changes reshape drug approval in 2025 and beyond?” including, of course, changes (i.e., reductions) in regulations. It shouted out APC’s blueprint (incorrectly calling it a “report,” but we’re OK with that), and it quoted APC’s Scott Brunner from our May 12 press briefing introducing the blueprint.